Hanmi Pharm Accelerates with R&D... 19 Research Results Released in the First Half of the Year

Hanmi Pharmaceutical continues its research and development (R&D)-focused management by presenting 19 research results at six international conferences in the first half of the year.

Researchers at Hanmi Pharmaceutical R&D Center are presenting posters at major international conferences held in the first half of this year, including the American Association for Cancer Research (AACR - top two photos), the European Association for the Study of the Liver (EASL - bottom left), and the Endocrine Society (ENDO - bottom right).
[Photo by Hanmi Pharmaceutical]

Hanmi Pharmaceutical announced on the 13th that it participated in the American Association for Cancer Research (AACR, 7 presentations), the Endocrine Society (ENDO, 3 presentations), the European Association for the Study of the Liver (EASL, 2 presentations), the American Thoracic Society (ATS, 1 presentation), the American Society for Clinical Pharmacology and Therapeutics (ASCPT, 1 presentation), and the American Society of Echocardiography (ASE, 1 presentation) during the first half of this year, presenting a total of 19 innovative research results including 4 presentations by partner companies. These results are based on Hanmi’s main pipelines in oncology, metabolic diseases, and rare diseases, and the company plans to accelerate the development of global innovative new drugs based on these findings.

First, at AACR held in April, Hanmi Pharmaceutical attracted attention by presenting the largest number of oncology research results among domestic companies, with 7 presentations. Along with demonstrating the efficacy of Hanmi’s oncology new drugs under development, research results on messenger RNA (mRNA)-based cancer vaccines, developed as a new modality (therapeutic approach), were also showcased. It was explained that through mRNA-based technology, antigens are effectively presented, showing potential as an anticancer therapy via immune response.

Next, at ATS in May and EASL last month, three research results on ‘LAPS Triple Agonist (LAPSTripleagonist),’ being developed as a treatment for non-alcoholic steatohepatitis (NASH), were disclosed. Hanmi Pharmaceutical confirmed that LAPSTripleagonist directly improved ‘liver fibrosis,’ a key indicator in NASH treatment, and also secured data supporting the possibility of developing a treatment for idiopathic pulmonary fibrosis (IPF).

Additionally, at EASL, detailed Phase 2a clinical results of another NASH treatment, ‘LAPS Dual Agonist (LAPSGLP/GCG agonist),’ which Hanmi Pharmaceutical licensed to MSD (Merck & Co., USA) in 2020 for up to $8.7 billion (approximately 1.1053 trillion KRW, with a $10 million upfront payment), were revealed through an oral presentation led by MSD. The results confirmed that the dual agonist showed superior efficacy in weight loss and reduction of liver fat content compared to the comparator, semaglutide.

Furthermore, at ENDO last month, research results on two rare disease drug candidates, including a treatment for short bowel syndrome being developed as the world’s first once-monthly formulation, were presented, demonstrating the excellent efficacy of these innovative new drugs and proposing a new treatment paradigm that can dramatically reduce patients’ dosing frequency.

In addition, at ASE, Professor Deokhyun Kang from Seoul Asan Medical Center presented Phase 4 clinical trial results using Hanmi Pharmaceutical’s hypertension treatment ‘Amozalatan,’ among others, showing that follow-up clinical research on commercialized products is steadily ongoing.

Hanmi Pharmaceutical Research Center Exterior [Photo by Hanmi Pharmaceutical]

A Hanmi Pharmaceutical official stated, “Recently, Hanmi Science, the holding company of the Hanmi Group, selected ‘innovative new drug R&D’ as one of the three core future growth engines and is pursuing a more aggressive R&D management policy. We will concentrate the company’s full capabilities on R&D management based on significantly expanded innovative new drug research achievements.”

This content was produced with the assistance of AI translation services.